These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 21484766

  • 1. Dose escalation of certolizumab pegol from 200 mg to 400 mg every other week provides no additional efficacy in rheumatoid arthritis: an analysis of individual patient-level data.
    Curtis JR, Chen L, Luijtens K, Navarro-Millan I, Goel N, Gervitz L, Weinblatt M.
    Arthritis Rheum; 2011 Aug; 63(8):2203-8. PubMed ID: 21484766
    [Abstract] [Full Text] [Related]

  • 2. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX.
    Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, Davies O, Stahl HD, Alten R.
    Rheumatology (Oxford); 2012 Jul; 51(7):1226-34. PubMed ID: 22344576
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
    [Abstract] [Full Text] [Related]

  • 5. Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
    Connock M, Tubeuf S, Malottki K, Uthman A, Round J, Bayliss S, Meads C, Moore D.
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):1-10. PubMed ID: 21047485
    [Abstract] [Full Text] [Related]

  • 6. RAPID3 (Routine Assessment of Patient Index Data 3) severity categories and response criteria: Similar results to DAS28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index) in the RAPID 1 (Rheumatoid Arthritis Prevention of Structural Damage) clinical trial of certolizumab pegol.
    Pincus T, Furer V, Keystone E, Yazici Y, Bergman MJ, Luijtens K.
    Arthritis Care Res (Hoboken); 2011 Aug; 63(8):1142-9. PubMed ID: 21485024
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, van der Heijde D, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study.
    Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, Koike T.
    Mod Rheumatol; 2014 Sep; 24(5):734-43. PubMed ID: 24593170
    [Abstract] [Full Text] [Related]

  • 12. Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial.
    Strand V, Mease P, Burmester GR, Nikaï E, Coteur G, van Vollenhoven R, Combe B, Keystone EC, Kavanaugh A.
    Arthritis Res Ther; 2009 Sep; 11(6):R170. PubMed ID: 19909548
    [Abstract] [Full Text] [Related]

  • 13. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase.
    Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB.
    Ann Rheum Dis; 2014 Dec; 73(12):2174-7. PubMed ID: 24972708
    [Abstract] [Full Text] [Related]

  • 14. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ, Schechtman J, Texter M, Fichtner A, de Longueville M, Chartash EK.
    J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
    [Abstract] [Full Text] [Related]

  • 15. Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safety.
    Mease PJ.
    Rheumatology (Oxford); 2011 Feb; 50(2):261-70. PubMed ID: 20871129
    [Abstract] [Full Text] [Related]

  • 16. Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension.
    Keystone E, Landewé R, van Vollenhoven R, Combe B, Strand V, Mease P, Shaughnessy L, VanLunen B, van der Heijde D.
    Ann Rheum Dis; 2014 Dec; 73(12):2094-100. PubMed ID: 23918037
    [Abstract] [Full Text] [Related]

  • 17. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Keystone E, Heijde Dv, Mason D, Landewé R, Vollenhoven RV, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K.
    Arthritis Rheum; 2008 Nov; 58(11):3319-29. PubMed ID: 18975346
    [Abstract] [Full Text] [Related]

  • 18. Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.
    Smolen JS, Emery P, Ferraccioli GF, Samborski W, Berenbaum F, Davies OR, Koetse W, Purcaru O, Bennett B, Burkhardt H.
    Ann Rheum Dis; 2015 May; 74(5):843-50. PubMed ID: 24431394
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L, Lapadula G, Mathieu A.
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [Abstract] [Full Text] [Related]

  • 20. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis.
    Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, Strand V, van Vollenhoven RF.
    Arthritis Rheum; 2009 Nov 15; 61(11):1592-600. PubMed ID: 19877104
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.